Cisplatin (CDDP): Benchmark DNA Crosslinking Agent for Cancer Research

Executive Summary: Cisplatin (CAS 15663-27-1) is a platinum-based chemotherapeutic compound widely used in cancer research for its robust DNA crosslinking and apoptosis-inducing properties (APExBIO). It exerts cytotoxic effects by forming intra- and inter-strand DNA crosslinks, leading to replication inhibition, p53 activation, and caspase-dependent apoptosis (Xu et al., 2023). Resistance to cisplatin is linked to redox signaling, notably the KEAP1/NRF2 pathway, and is a major hurdle in translational oncology. The agent is best solubilized in DMF at ≥12.5 mg/mL and should be stored as a powder at room temperature in the dark. Cisplatin remains the reference compound for apoptosis assays, tumor growth inhibition protocols, and chemo-resistance mechanistic studies.

Biological Rationale

Cisplatin (CDDP) is a first-line chemotherapeutic used in research and clinical settings for a variety of solid tumors, including head and neck squamous cell carcinoma (HNSCC), ovarian, and testicular cancers (Xu et al., 2023). Its efficacy is attributed to its ability to induce DNA damage and trigger cell death pathways. The compound is especially valued in the study of apoptosis, DNA damage response, and chemo-resistance mechanisms. In translational oncology, cisplatin-resistant models are employed to dissect pathways such as the KEAP1/NRF2 axis and to explore strategies for overcoming resistance (see comparison). Cisplatin’s broad cytotoxicity profile makes it a tool of choice for in vitro and in vivo assays.

Mechanism of Action of Cisplatin

Cisplatin’s primary mechanism involves covalently binding to DNA, forming both intra- and inter-strand crosslinks at guanine N7 positions (APExBIO). This blocks DNA replication and transcription, leading to cell cycle arrest and apoptosis. The DNA damage response activates p53, which upregulates pro-apoptotic factors. Cisplatin also increases reactive oxygen species (ROS) within cells, contributing to oxidative stress and further promoting apoptosis via ERK-dependent and caspase-dependent pathways (notably caspase-3 and caspase-9). Resistance can emerge through enhanced DNA repair, antioxidant responses (e.g., NRF2 pathway activation), and reduced drug uptake. The KEAP1/NRF2/JNK axis has been identified as a central mediator of cisplatin resistance in HNSCC (Xu et al., 2023).

Evidence & Benchmarks

• Cisplatin's half-maximal inhibitory concentration (IC50) varies by cell line, but robust cytotoxicity is observed in HNSCC and ovarian cancer models (Xu et al., 2023).
• In vivo, intravenous administration of cisplatin at 5 mg/kg on days 0 and 7 significantly inhibits tumor growth in xenograft models (APExBIO).
• High TNFAIP2 expression correlates with decreased ROS and increased cisplatin resistance in HNSCC (Xu et al., 2023).
• siRNA targeting TNFAIP2 restores cisplatin sensitivity in 4NQO-induced HNSCC mouse models (Xu et al., 2023).
• Cisplatin is insoluble in water and ethanol but dissolves in DMF at concentrations ≥12.5 mg/mL with warming and sonication (APExBIO).
• DMSO inactivates cisplatin, leading to reduced cytotoxicity in cell-based assays (APExBIO).
• KEAP1/NRF2 pathway activation is a validated resistance mechanism, limiting cisplatin efficacy (Xu et al., 2023).

Applications, Limits & Misconceptions

Cisplatin is used in apoptosis assays, chemotherapy resistance studies, and tumor growth inhibition models. It is also a reference standard for DNA damage and caspase pathway research. The A8321 kit from APExBIO offers research-grade cisplatin for these applications (product page). While cisplatin is highly effective in many systems, resistance remains a challenge, especially in HNSCC and ovarian cancer. Antioxidant pathway activation, notably via KEAP1/NRF2, can hinder cisplatin-induced apoptosis. This article updates prior guides such as "Cisplatin: Benchmark DNA Crosslinking Agent for Cancer Research" by detailing the latest evidence for resistance mechanisms and workflow optimizations.

Common Pitfalls or Misconceptions

• DMSO as a solvent: DMSO inactivates cisplatin; use DMF for stock solutions (APExBIO).
• Storage conditions: Solutions are unstable; store cisplatin as a dry powder at room temperature, protected from light.
• ROS-independent apoptosis: In some resistant models, apoptosis is not mediated by ROS, limiting the compound's efficacy (Xu et al., 2023).
• Generalizing resistance mechanisms: Not all tumors develop cisplatin resistance via KEAP1/NRF2; alternative pathways exist.
• Cell line variability: Sensitivity to cisplatin varies significantly by cell type and genetic background.

Workflow Integration & Parameters

Cisplatin is typically prepared as a fresh stock in DMF (≥12.5 mg/mL) using gentle warming and ultrasonication. Avoid DMSO, as it inactivates the drug. For in vitro assays, dilute stocks into appropriate media immediately before use. For in vivo studies, intravenous dosing at 5 mg/kg on days 0 and 7 is standard for xenograft inhibition (APExBIO). Store powder in the dark at room temperature for optimal stability. The compound is routinely used in apoptosis assays and to model resistance; see the Cisplatin (SKU A8321) workflow guide for troubleshooting and protocol optimization. This article clarifies solvent compatibility and resistance benchmarks beyond standard protocol guides such as "Cisplatin (CDDP) in Translational Oncology: Mechanistic Insights".

Conclusion & Outlook

Cisplatin (CDDP) remains a cornerstone DNA crosslinking agent for cancer research, enabling robust investigation of apoptosis, DNA damage, and chemoresistance mechanisms. Despite the challenge of resistance—particularly via KEAP1/NRF2 signaling—ongoing research continues to yield strategies for restoring sensitivity. The A8321 kit from APExBIO provides a validated and reliable reagent for experimental oncology workflows. For advanced mechanistic discussion and emerging resistance pathways, see also "Cisplatin in Cancer Research: Ferroptosis, Apoptosis, and Beyond", which this article extends by focusing on benchmark protocols and resistance biomarkers.